leon TVM SeriesA press release 27.07 - Startseite - BioM · Practice)! compliant nanotechnology!...
Transcript of leon TVM SeriesA press release 27.07 - Startseite - BioM · Practice)! compliant nanotechnology!...
News Release
leon-‐nanodrugs GmbH raises EUR 18.5 million in Series A financing
TVM Capital Life Science leads international syndicate of investors -‐ an additional EUR 3 million
investment is expected later in 2015
Munich, 27 July 2015 — leon nanodrugs GmbH today announced that it completed the first
closing of its Series A preferred stock offering at EUR 18.5 million. The financing was led by
TVM Capital Life Science, based in Munich and Montreal, with participation from Signet
Healthcare Partners (USA), LifeCare Partners (Switzerland), CD-‐Venture (Germany), Albany
Private Equity Holding (Australia), and a non-‐disclosed Family Office from Germany. Dr.
Hubert Birner, Managing Partner, and Stefan Fischer, General Partner & CFO, TVM Capital
Life Science, James Gale, Managing Director, Signet Healthcare Partners, Dr. Gerhard Ries,
Managing Partner, LifeCare Partners, Dr. Frank Mathias, CEO, Medigene AG, and Dr. Bernd
Baumstümmler, CEO, Instillo Group, will be joining the Board of Directors.
leon-‐nanodrugs was founded by a group of experienced drug development professionals in
mid-‐2011. The company focuses on the reformulation of approved or promising small
molecule and protein drug candidates based on its patented and award winning MJR-‐
nanotechnology-‐platform. leon-‐nanodrugs develops novel oral and parenteral formulations
by using GMP (Good Manufacturing Practice) compliant nanotechnology to improve
bioavailability, solubility as well as dissolution rates. leon-‐nanodrugs will use the proceeds of
this Series A financing to expand its profitable service business and to enter into high margin
co-‐development deals with pharmaceutical partners.
Dr. Wolfgang Beier, Medical Director and Co-‐Founder, explains: “With our unique network of
interdisciplinary drug-‐development capabilities and our leading nanotechnology platform,
we are a reformulation expert for high barrier generics for proactive product life-‐cycle-‐
management or line-‐extensions as well as the development of novel nano-‐ and micronized
drugs.”
Cornelia Beier, Managing Director and Co-‐Founder of leon-‐nanodrugs adds: ”We are proud
to partner with TVM Capital Life Science’s experienced investment team as the lead investor
for our Series A financing. Their global reach will offer us unique opportunities to drive the
commercialization of our product candidates on an international scale.”
“This is TVM Capital Life Science’s first investment into a German company since 2009 and
we are very pleased to reinforce our footprint as a lead-‐investor in the German market,
especially as we are joined in this financing by reputable investors who have co-‐invested
with us over many years in Germany and abroad”, states Dr. Hubert Birner, Managing
Partner with TVM Capital Life Science in Munich and Montreal. ”leon-‐nanodrugs provides an
exciting next-‐generation-‐nanotechnology reformulation platform, validated by multiple
service collaborations with prominent pharma partners, that will certainly change this
market segment in the future – congratulations to the team at leon-‐nanodrugs for achieving
one of the largest Series A financings this year.”
About leon-‐nanodrugs leon-‐nanodrugs GmbH (based in Munich) is a nanotechnology-‐based drug development company focused on reformulations and reinventions of drugs on a contract or co-‐development basis. Based on its “network of expertise”, leon-‐nanodrugs can provide a 360 degree service range – from concept to product approval. The core business is the reformulations to develop novel oral and parenteral formulations and innovative drug combinations, which have not been possible in the past due to low bioavailability caused by low solubility of APIs. The 2014 CPhI Pharma Awards for Best Innovation in Formulation was won by MJR PharmJet GmbH, leon nanodrugs’ exclusive reformulation service partner for its patented nanotechnology. www.leon-‐nanodrugs.com Contact Cornelia Beier, Managing Director leon-‐nanodrugs GmbH c.beier@leon-‐nanodrugs.com +49 89 414248899-‐0 About TVM Capital Life Science TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-‐years of transatlantic investment track record and in excess of US$1.3bn under management. TVM Capital Life Science currently invests from its 7th fund
generation, TVM Life Science Ventures VII, with an integrated team of investment professionals from Munich and Montreal. www.tvm-‐capital.com or www.tvm-‐lifescience.com Media Contact Monika Schlesinger Global Communications TVM Capital Life Science & Healthcare schlesinger@tvm-‐capital.com +49 89 998992-‐0 About Signet Healthcare Partners Founded in 1998, Signet Healthcare Partners provides growth capital to commercial-‐stage healthcare companies around the world. Over the past 16 years, Signet has organized three funds and completed investments in 42 companies with 25 exits. The team, comprised of five professionals with principal offices in New York City, brings over 100 years of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For more information, please visit Signet online at www.signethealthcarepartners.com.
About LifeCare Partners LifeCare Partners is an independent investment firm providing financing to private and public life science companies. LifeCare Partners targets the entire life science industry with special focus on medical technology, diagnostics, biopharmaceuticals, food & nutrition, industrial biotechnology, biomaterials, e-‐health and bioenergy. Based in Basel, the LifeCare Partners team has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry. For more information, visit www.lifecarevc.com